A bill to amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.
Biologics Market Transparency Act of 2022
This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
Referred to the Subcommittee on Health.
Received in the Senate.
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line